Executive summary

In this August 2026 update we revisit a married-founder who monetized $7.6 million of qualified small business stock (QSBS) by funding a charitable remainder unitrust (CRUT). The core outcome is unchanged: the CRUT converted concentrated QSBS into diversified, spendable capital, produced a lifetime payout stream, generated a current-year charitable deduction that materially reduced paper AGI in the funding year, and preserved a charitable remainder—while easing estimated-tax friction for subsequent years. The 2026 twist: higher prevailing interest rates and elevated IRS scrutiny materially changed remainder valuations and documentation priorities, so advisers must re-run models and harden the audit file.

Background: the client situation and constraints

The client remains a 58‑year‑old founder married filing jointly. In our original June 2026 scenario the household had modest wage income (~$180,000 in 2025) but a concentrated QSBS block valued at $7.6 million with a $400,000 basis. An outright sale in a single year would have realized roughly $7.2 million of gain and risked pushing the taxpayers into top marginal rates, triggering larger Net Investment Income Tax (NIIT) and Medicare surtax exposure and forcing much higher estimated-tax payments for 2026.

Objectives were the same and practical:

  • Convert illiquid, concentrated QSBS into diversified capital;
  • Avoid a single-year spike in taxable income and related surtaxes;
  • Maintain a philanthropic legacy;
  • Reduce estimated-tax friction and underpayment risk.

Challenge

The technical problem remained: monetize a large QSBS position without incurring an immediate crippling tax bill or complicating retirement cash flow. By August 2026 two external forces amplified the operational challenge:

  • Macro-driven increase in the Section 7520-linked discount rate reduced charitable deduction present values compared with 2024–25 modeling;
  • Heightened IRS attention to high‑dollar charitable and in‑kind transfers increased the need for contemporaneous valuation, trustee independence documentation, and QSBS eligibility memos.

Solution

The advisor team again recommended funding a non‑grantor CRUT with the QSBS shares and directing the trustee to sell inside the trust. Key reasons and 2026 nuances:

  • Sales inside a properly structured CRUT remain tax‑exempt at the trust level, producing liquidity without immediate trust‑level tax.
  • Funding the CRUT creates an immediate charitable income tax deduction for the donors equal to the present value of the remainder interest—this remains powerful but is now more sensitive to current Section 7520 rates and mortality assumptions than it was two years ago.
  • A unitrust payout (we modeled 10% in this case) produces predictable lifetime cash flow, smoothing income and simplifying estimated‑tax planning compared with a one‑year spike.
  • Remainder flows to charities, meeting legacy goals.

Why still choose a CRUT in 2026? If the donor values lifetime income plus a philanthropic remainder and QSBS Section 1202 coverage is incomplete or uncertain, a CRUT remains a high‑utility tool. But in 2026 we place extra emphasis on pre‑transfer 1202 analysis and documentation because transferring eligible QSBS into a non‑grantor trust can foreclose the individual’s ability to claim the exclusion.

Implementation — timeline and mechanics (updated Aug 2026)

  1. June–July 2025 (planning): Set target payout (10% CRUT), run initial Section 7520–based remainder projections and sensitivity tables. Model estimated‑tax safe harbors for 2026–2028.
  2. July–Aug 2025 (drafting & pre‑work): Confirm trust language, select an independent corporate trustee with transaction experience, and prepare contemporaneous QSBS documentation (acquisition history, board consents, cap‑table snapshots).
  3. September 2025 (funding): Transfer the QSBS to the CRUT. Trustee executed a prompt arm’s‑length sale and reinvested proceeds into a diversified, income‑oriented portfolio.
  4. Q4 2025–2026 (reporting & payouts): Donors claimed the charitable deduction to the extent allowed by AGI limits and carried forward excesses. CRUT began annual unitrust distributions to the donors.
  5. 2026 (post‑funding calibration): With the 7520 environment changed, advisers reran remainder valuations and tightened file documentation; estimated‑tax safe harbors and withholding adjusted to reflect the shifted tax profile.

Numbers — updated, illustrative (modeled Aug 2026)

These figures are illustrative and client‑specific; advisers must re‑run with live tables and the current monthly Section 7520 rate.

  • QSBS proceeds inside trust: $7.6M
  • Cost basis: $400k; embedded gain: $7.2M
  • Chosen CRUT payout rate: 10%
  • Illustrative present‑value charitable remainder in June 2026 model: ~ $2.4M (sensitive). By August 2026, higher market rates reduced the same remainder PV in our re‑runs to roughly $1.8M–$2.0M under typical mortality assumptions—meaning donors saw a materially smaller immediate charitable deduction versus earlier 2025 projections.
  • Tax effect: the (reduced) charitable deduction still lowered reported AGI in the funding year enough to avoid crossing key surtax thresholds in this household’s profile, but the cushion is thinner than it would have been at lower 7520 rates.
  • Estimated‑tax strategy: re‑calibration allowed the household to use prior‑year safe harbor (100%/110% rules) and updated withholding to reduce quarterly payments without triggering underpayment penalties.

Results and client outcomes

  • Liquidity: The CRUT sale converted an illiquid, concentrated QSBS stake into a diversified portfolio that funds predictable annual distributions—this household received roughly 10% of trust value annually, net of trustee fees.
  • Tax posture: The charitable deduction materially reduced paper AGI in the funding year; because 7520 had moved higher, the deduction was smaller than a 2024 model would have projected, but still sufficient to avoid surtax triggers for this client.
  • Estimated taxes: Proactive recalculation allowed the couple to lower 2026 estimated payments under safe‑harbor calculations, improving near‑term cash flow while creating a roadmap to address future taxable CRUT payouts.
  • Philanthropy preserved: The named charities retained a substantial remainder—supporting the client’s legacy objective while enabling lifetime cash.

2026‑specific considerations and updated best practices

Between 2024–Aug 2026, three practical realities matter for advisers:

  • Section 7520 sensitivity is real. Higher federal short‑term rates over 2022–2026 mean present‑value charitable remainders have shrunk; always rerun valuations on the actual month’s IRS Section 7520 table and produce ±0.5% and ±1.0% sensitivity scenarios.
  • Documentation and trustee selection now matter more. Expect IRS examiners to scrutinize high‑dollar in‑kind transfers and noncash charitable vehicles. Use independent corporate trustees with documented sale authority, contemporaneous memos explaining charitable intent, and clean QSBS acquisition histories.
  • Estimate safe harbors with care. The basic safe‑harbor rules remain: you can avoid underpayment penalties by paying 90% of current year tax or 100% of prior year tax (110% for higher‑income taxpayers). With a CRUT you shift tax from a lump sum to a stream—update multi‑year projections so you don’t chase a one‑year fix that creates future underpayments.

Lessons learned

  1. Run multiple 7520 scenarios before funding: a small move in the monthly rate materially changes the donor’s charitable deduction and lifetime income math.
  2. Do the 1202 homework first: determine the portion of QSBS that clearly qualifies for Section 1202 exclusion before transferring any shares into a non‑grantor trust.
  3. Pick a trustee who can sell large blocks quickly and document that capability in the file to avoid market‑execution risk.
  4. Revisit estimated‑tax safe harbors across a multi‑year horizon; solving year‑one cash flow without planning for later taxable payouts is a recipe for surprises.
  5. Build an audit‑ready binder: trust instrument, trustee acceptance, QSBS history, valuation memos, 7520 sensitivity tables, and contemporaneous charitable intent memoranda.

When not to use this approach

A CRUT is not the default. Use it when the client values lifetime income, philanthropic remainder, and AGI management and when Section 1202 coverage is incomplete or uncertain. If the entire block clearly qualifies for the full 1202 exclusion and the exclusion value exceeds the expected charitable deduction benefit, an outright sale (or a targeted sale of covered tranches by the individual) may be superior. Also avoid CRUT funding if the donor needs unrestricted immediate cash faster than trustee sale mechanics can deliver.

Practical checklist for advisors (run now)

  • Confirm QSBS Section 1202 coverage at the tranche level and whether transfer affects eligibility.
  • Run Section 7520–based remainder calculations using the current monthly rate; produce sensitivity tables at ±0.5% and ±1.0%.
  • Model tax outcomes across multi‑year scenarios (MFJ or MFS), NIIT and Medicare surtax triggers, and safe‑harbor thresholds (100%/110%).
  • Plan trustee sale mechanics: pre‑authorize market makers, negotiated buyers or block‑trade methods and document execution authority.
  • Recalculate estimated‑tax safe harbors and update withholding immediately after funding to prevent underpayment or overpayment mistakes.
  • Assemble contemporaneous memos: QSBS history, trustee independence, valuation, 7520 sensitivity, charitable beneficiary designations and estimated‑tax worksheets.

Conclusion

For this founder, a CRUT funded with QSBS still delivered liquidity, a steady income stream, an immediate charitable deduction that reduced paper AGI and a way to smooth tax exposure over time. The August 2026 reality is less forgiving: higher rates have reduced charitable deduction headroom and IRS scrutiny has tightened. Do the math with current 7520 tables, document the QSBS story before you transfer, choose a trustee who can execute promptly, and treat estimated‑tax planning as a multi‑year flow problem—not a one‑time fix.

Can funding QSBS into a CRUT preserve Section 1202 exclusion?

Not automatically. Transferring QSBS into a non‑grantor CRUT generally results in the trust—rather than the original shareholder—selling the stock, and Section 1202 exclusion rights are tethered to the original taxpayer’s qualifying ownership. Always do a tranche‑level 1202 analysis before funding; if a meaningful exclusion is likely, consider selling the eligible shares personally or waiting until the exclusion is realized.

How are CRUT payouts taxed to the recipient?

Payouts follow the standard four‑tier ordering rules: ordinary income first, then capital gains, then tax‑free return of principal. Because the CRUT can sell appreciated property tax‑exemptly and then reinvest, the timing and character of taxable income to beneficiaries can vary—model expected character each year to set correct withholding and estimated‑tax plans.

What payout rate should we pick (5% vs 10% vs higher)?

No universal answer. Lower payout rates increase the charitable remainder and the immediate deduction; higher rates raise lifetime cash but reduce remainder and deduction. Given 2026’s tighter 7520 environment, run sensitivity on payout rates and include a worst‑case 7520 assumption in your planning so donors see the range of possible deductions and incomes.

Will funding a CRUT improve estimated‑tax cash flow immediately?

Yes—if the charitable deduction meaningfully lowers AGI in the funding year, you can reduce estimated payments or adjust withholding under the safe‑harbor rules. But because CRUT payouts are taxable in future years, update projected safe‑harbor calculations for the next 3–5 years to avoid creating underpayment exposure later.

What documentation should we keep in the file?

Keep the trust instrument, trustee acceptance letter, QSBS acquisition history and cap‑table snapshots, contemporaneous Section 1202 analysis, valuation reports, Section 7520 calculation memos (with sensitivity tables), charitable beneficiary designations, and estimated‑tax recalculation worksheets. This folder is indispensable if the IRS asks questions.